Trial · NCT01996865
Adverse events882
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 882
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Induction Period: Lenalidomide + Rituximab | 77 | 500 | |
| other | Anaemia | Blood and lymphatic system disorders | Arm A: Lenalidomide + Rituximab | 12 | 134 | |
| other | Anaemia | Blood and lymphatic system disorders | Arm B: Rituximab | 8 | 132 | |
| other | Leukopenia | Blood and lymphatic system disorders | Induction Period: Lenalidomide + Rituximab | 67 | 500 | |
| other | Leukopenia | Blood and lymphatic system disorders | Arm A: Lenalidomide + Rituximab | 13 | 134 | |
| other | Leukopenia | Blood and lymphatic system disorders | Arm B: Rituximab | 9 | 132 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Induction Period: Lenalidomide + Rituximab | 33 | 500 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Arm A: Lenalidomide + Rituximab | 5 | 134 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Arm B: Rituximab | 3 | 132 | |
| other | Neutropenia | Blood and lymphatic system disorders | Induction Period: Lenalidomide + Rituximab | 217 | 500 | |
| other | Neutropenia | Blood and lymphatic system disorders | Arm A: Lenalidomide + Rituximab | 54 | 134 | |
| other | Neutropenia | Blood and lymphatic system disorders | Arm B: Rituximab | 22 | 132 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Induction Period: Lenalidomide + Rituximab | 74 | 500 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Arm A: Lenalidomide + Rituximab | 9 | 134 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Arm B: Rituximab | 5 | 132 | |
| other | Tinnitus | Ear and labyrinth disorders | Induction Period: Lenalidomide + Rituximab | 5 | 500 | |
| other | Tinnitus | Ear and labyrinth disorders | Arm A: Lenalidomide + Rituximab | 7 | 134 | |
| other | Tinnitus | Ear and labyrinth disorders | Arm B: Rituximab | 3 | 132 | |
| other | Hypothyroidism | Endocrine disorders | Induction Period: Lenalidomide + Rituximab | 14 | 500 | |
| other | Hypothyroidism | Endocrine disorders | Arm A: Lenalidomide + Rituximab | 7 | 134 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01996865/events